Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMMJTYW)

Drug Name
Darbepoetin alfa Drug Info
Synonyms Aranesp (TN)
Indication
Disease Entry ICD 11 Status REF
Anemia 3A00-3A9Z Approved [1]
Carcinoma 2A00-2F9Z Approved [2]
Chronic kidney disease GB61 Investigative [3]
Nephropathy GC2Z Investigative [4]
Therapeutic Class
Antianemic Agents
Cross-matching ID
TTD Drug ID
DMMJTYW

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Erythropoietin Receptor (EPOR) TTAUX24 EPOR_HUMAN Agonist [5]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Erythropoietin Receptor (EPOR) DTT EPOR 5.166 4.594 4.469 4.763
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Anemia
ICD Disease Classification 3A00-3A9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Erythropoietin Receptor (EPOR) DTT EPOR 7.04E-01 0.11 0.27
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
2 DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group. Radiother Oncol. 2018 Apr;127(1):12-19.
3 A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19;361(21):2019-32.
4 Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan. Clin Exp Nephrol. 2021 Feb;25(2):110-119.
5 A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation. Eur J Biochem. 1999 Jul;263(2):410-9.